KEY POINTS • The prognosis for patients with mCRPC has improved over the last 
few years due to the introduction of novel agents. • The optimal sequence of 
administering these therapeutic agents remains as a moving target and is not 
well established. Decisions are usually made according to patients' clinical 
conditions and disease characteristics, and the safety profile and availability 
of new drugs. • Recently, cabazitaxel improved outcomes in the third-line 
setting after docetaxel and an ARTA. Olaparib is an additional option for 
second- and third-line treatment in those with alterations in BRCA1, BRCA2, and 
ATM. • Understanding the mechanisms of resistance may provide a rationale for 
suggesting specific strategies. • A subset of patients may benefit from 
molecularly targeted therapies, which highlights the importance of genomic 
testing in the castration-resistant setting. • Immunotherapy may provide benefit 
to some subsets of patients, such as those with MSI-high tumors. Studies 
regarding combination therapy with immune checkpoint inhibitors are ongoing.